{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Fu C"],"funding":["\"Financial Support for Selected Researchers Back from Abroad (2012)\" from Liaoning Province"],"pagination":["1011-1025"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7935791"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["112(3)"],"pubmed_abstract":["Myeloid-derived suppressor cells (MDSCs) are responsible for antitumor immunodeficiency in tumor-bearing hosts. Primarily, MDSCs are classified into 2 groups: monocytic (M)-MDSCs and polymorphonuclear (PMN)-MDSCs. In most cancers, PMN-MDSCs (CD11b<sup>+</sup> Ly6C<sup>low</sup> Ly6G<sup>+</sup> cells) represent the most abundant MDSC subpopulation. However, the functional and phenotypic heterogeneities of PMN-MDSC remain elusive, which delays clinical therapeutic targeting decisions. In the 4T1 murine tumor model, CD11b<sup>+</sup> Ly6G<sup>low</sup> PMN-MDSCs were sensitive to surgical and pharmacological interventions. By comprehensively analyzing 64 myeloid cell-related surface molecule expression profiles, cell density, nuclear morphology, and immunosuppressive activity, the PMN-MDSC p"],"journal":["Cancer science"],"pubmed_title":["CD205<sup>+</sup> polymorphonuclear myeloid-derived suppressor cells suppress antitumor immunity by overexpressing GLUT3."],"pmcid":["PMC7935791"],"funding_grant_id":["88030312004"],"pubmed_authors":["Zheng K","Fu C","Ma S","Gu X","Zhang Y","Fu Z","Tang S","Zhou D","Jiang C","Xia C","Lyu S"],"additional_accession":[]},"is_claimable":false,"name":"CD205<sup>+</sup> polymorphonuclear myeloid-derived suppressor cells suppress antitumor immunity by overexpressing GLUT3.","description":"Myeloid-derived suppressor cells (MDSCs) are responsible for antitumor immunodeficiency in tumor-bearing hosts. Primarily, MDSCs are classified into 2 groups: monocytic (M)-MDSCs and polymorphonuclear (PMN)-MDSCs. In most cancers, PMN-MDSCs (CD11b<sup>+</sup> Ly6C<sup>low</sup> Ly6G<sup>+</sup> cells) represent the most abundant MDSC subpopulation. However, the functional and phenotypic heterogeneities of PMN-MDSC remain elusive, which delays clinical therapeutic targeting decisions. In the 4T1 murine tumor model, CD11b<sup>+</sup> Ly6G<sup>low</sup> PMN-MDSCs were sensitive to surgical and pharmacological interventions. By comprehensively analyzing 64 myeloid cell-related surface molecule expression profiles, cell density, nuclear morphology, and immunosuppressive activity, the PMN-MDSC p","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Mar","modification":"2025-04-04T18:37:22.527Z","creation":"2025-04-04T18:37:22.527Z"},"accession":"S-EPMC7935791","cross_references":{"pubmed":["33368883"],"doi":["10.1111/cas.14783"]}}